News

Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year
Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in ...
Clinical Trials Arena on MSN1d
Novo Nordisk ramps up obesity fight, advances amycretin to Phase III
Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity ...
Fierce Biotech1d
Novo Nordisk plots phase 3 trials for next-gen obesity asset amycretin
Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...
Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight ...
Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company
Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory ...
The Pharma Letter1d
Novo Nordisk to advance SC and oral amycretin development
Novo Nordisk late Thursday announced that it will advance subcutaneous (SC) and oral amycretin into Phase III development in ...
Devdiscourse2d
Novo Nordisk's Next-Gen Obesity Treatment: A New Hope in Weight Loss
Novo Nordisk plans to initiate late-stage trials for its next-gen weight-loss drug, amycretin, by early 2026. The drug mimics ...
BioPharma Dive1d
Novo, searching for a spark, plans late-stage trials for amylin drug
The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...
Devdiscourse2d
Novo Nordisk Set to Launch Late-Stage Trials for Weight Management Drugs
Novo Nordisk has announced plans to initiate late-stage trials for its amycretin injection and oral drugs targeting adults ...
Why Novo Nordisk Stock Pumped Higher on Thursday
Positive news from the laboratory was the wind beneath the wings of Novo Nordisk (NYSE: NVO) stock on Thursday. The ...
Novo Nordisk plans to start late-stage trials for experimental obesity drug amycretin
Novo Nordisk said on Thursday it plans to start late-stage trials of amycretin injection and oral drugs during the first ...
Novo Nordisk A/S: Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies. The ...